Search Results 81-90 of 18358 for alopecia

  1. A Study Of IBI363 In Subjects With Advanced Solid Malignancies - Mayo Clinic

    0 (except for alopecia, fatigue, pigmentation and other conditions with no safety risk according to investigator' discretion) or baseline prior to the first ...

  2. Chemotherapy for breast cancer - Mayo Clinic

    Efficacy of scalp cooling in preventing and recovering from chemotherapy-induced alopecia in breast cancer patients: The HOPE study. Frontiers in Oncology ...

  3. Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant - Mayo Clinic

    ... alopecia). Patient is currently receiving or has received systemic ... Exception to this criterion: patients with any grade of alopecia are allowed to enter the ...

  4. Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer - Mayo Clinic

    ... alopecia - Patients who are receiving any other investigational agents - Patients with uncontrolled intercurrent illness - Patients who cannot discontinue ...

  5. Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors - Mayo Clinic

    ... alopecia, bone marrow and organ functions); Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the ...

  6. A Study of a Personalized Neoantigen Cancer Vaccine - Mayo Clinic

    ... alopecia, and hypothyroidism that is controlled with hormone replacement therapy). Active, known, or suspected autoimmune disease. Note: Patients with type ...

  7. A Study to Evaluate Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer - Mayo Clinic

    Exceptions: Residual alopecia and Grade 2 peripheral neuropathy are allowed. Concurrent use of strong and moderate inducers and/or strong inhibitors of ...

  8. Study Of SIM0500 Alone In Participants With Relapsed Or Refractory Multiple Myeloma - Mayo Clinic

    Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy. 2 ...

  9. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and Combined with Chemotherapy or Tislelizumab to Treat Patients with Metastatic Solid Tumors - Mayo Clinic

    Low-grade (< Grade 3) toxicities, such as neuropathy from prior treatments, manageable electrolyte abnormalities and lymphopenia, alopecia and vitiligo are ...

  10. Head and neck cancers - Doctors and departments - Mayo Clinic

    ... Alopecia areata, Melasma. Show more areas of focus for Ashley B. Wentworth, M.D.. Josh P. Wiedermann, M.D.. Otolaryngologist. Rochester ...